PREZCOBIX
LaunchNDAORALTABLET, FOR SUSPENSION
Approved
Feb 2026
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
PREZCOBIX by Johnson & Johnson is fixed-dose combinations of an hiv-1 antiviral drug, darunavir and a cyp3a inhibitor, cobicistat [see ]. Approved for hiv-1 in treatment-naïve, treatment-experienced adults, older weighing at least 15 kg with no darunavir resistance-associated substitutions (v11i and 10 more indications. First approved in 2026.
Drug data last refreshed 19h ago
Mechanism of Action
fixed-dose combinations of an HIV-1 antiviral drug, darunavir and a CYP3A inhibitor, cobicistat [see ].
Indications (13)
Worked on PREZCOBIX at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.